Takeda has appointed Julie Kim as its new Representative Director, President and Chief Executive Officer, completing an 18-month leadership transition. Shareholders elected Kim as an internal director at the company's 150th Annual General Meeting of Shareholders in Osaka, Japan, and the Board of Directors subsequently named her to the top role, effective June 24, 2026. Former President and CEO Christophe Weber retired from the company and the Board after 12 years of service. The Board also added three new external directors: Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels, bringing the total number of external directors to eight out of 11 members. Takeda highlighted plans for three major product launches in the next 12 months and a pipeline of five additional late-stage assets as it enters its next growth phase.
Takeda Pharmaceutical Co. Ltd.Leadership transition completed with new CEO and board additions, plus plans for major product launches and late-stage pipeline.